FDA approves Biogen hemophilia drug


Biogen's (BIIB) Elocate has been approved for "the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A."

Biogen declares Elocate is "the only treatment for hemophilia A to reduce the frequency of bleeding episodes with prophylactic infusions every three to five days."

The drug is expected to be launch in the U.S. in July.

BIIB +0.5% AH.

From other sites
Comments (1)
  • duhaus
    , contributor
    Comments (320) | Send Message
     
    Ever since the February biotech sell off, Biogen has quietly and steadily been gaining back. Hopefully this will help spur a nice momentum surge.
    6 Jun 2014, 09:35 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs